Apogee Therapeutics, Inc. Common Stock
APGE
$134.84
+0.26%
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing optimized biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. The company differentiates itself through antibody engineering aimed at improving efficacy and dosing convenience, targeting well-established mechanisms of action. The current investor narrative is dominated by AbbVie's $10.9 billion acquisition announced in June 2026, which has driven a sharp re-rating of the stock and raised questions about the deal's strategic fit and long-term accretion. The acquisition is expected to extend AbbVie's immunology dominance, though meaningful earnings accretion is not anticipated until 2032, creating a mix of optimism and caution among investors.…
APGE
Apogee Therapeutics, Inc. Common Stock
$134.84
Related headlines
Investment Opinion: Should I buy APGE Today?
Rating: Hold. The acquisition by AbbVie provides a price floor, but the current price is near the average analyst target of $130.53, implying limited upside. The consensus recommendation is 'hold' with a mean rating of 2.6, reflecting a neutral stance. The thesis is that the stock is fairly valued at current levels, with the acquisition premium already priced in, and investors should wait for a better entry point or clarity on the deal's completion.
Sign up to view all
APGE 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock is trading near its high with limited upside to analyst targets, and the acquisition premium is largely priced in. The lack of revenue and reliance on the acquisition's success introduce significant uncertainty. If the acquisition closes and the pipeline progresses positively, the stock could see modest gains; however, any negative development could lead to a sharp decline. The stance would upgrade to bullish if the acquisition closes and the stock trades at a discount to the deal value, or if new clinical data significantly enhances the pipeline's value. It would downgrade to bearish if the acquisition fails or clinical trials show adverse results.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Apogee Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $130.53 and implied upside of -3.2% versus the current price.
Average Target
$130.53
0 analysts
Implied Upside
-3.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$81 - $137
Analyst target range
Analyst coverage includes 12 analysts, with a consensus recommendation of 'hold' (mean rating 2.6). The average target price is $130.53, which is 2.9% below the current price of $134.49, implying a slight downside. The distribution includes 0 buys, 0 holds, and 0 sells, but the recommendation mean of 2.6 suggests a neutral stance. The target price range is $81.00 to $137.00, with the low target implying a 39.8% downside and the high target implying a 1.9% upside. The narrow spread between the average and high target suggests analysts see limited upside from current levels, likely due to the acquisition price being near the current market price. Recent ratings actions show a wave of downgrades on June 22-24, 2026, with firms like TD Cowen, Stifel, Mizuho, and Guggenheim moving from Buy to Hold/Neutral, reflecting the post-acquisition re-rating. This pattern indicates that analysts are adjusting to the acquisition terms, which may cap the stock's upside.
Bulls vs Bears: APGE Investment Factors
The bull case for APGE is anchored by the acquisition premium, which provides a price floor and reduces downside risk, while the bear case centers on the lack of revenue, delayed accretion, and limited upside to analyst targets. Currently, the bear case has stronger evidence because the stock is trading near its high with minimal upside, and analysts have downgraded the stock post-acquisition. The most critical tension is whether the acquisition will close as expected and whether AbbVie can successfully integrate and commercialize Apogee's pipeline to justify the $10.9 billion price tag. If the deal closes without issues, the stock is likely to remain near current levels; if it fails, the stock could drop significantly toward the 52-week low of $34.34.
Bullish
- Acquisition Premium Locks in Value: AbbVie's $10.9 billion acquisition, announced June 2026, provides a clear floor for the stock. The current price of $134.49 is within 0.1% of the 52-week high of $134.58, reflecting market confidence in the deal's completion and terms.
- Strong Balance Sheet with Minimal Debt: Apogee has a current ratio of 26.57 and a debt-to-equity ratio of 0.0098, indicating a robust cash position and negligible leverage. This financial stability reduces bankruptcy risk during the clinical development phase.
- Pipeline Targeting Large I&I Markets: The company's focus on atopic dermatitis, asthma, and COPD addresses multi-billion-dollar markets. Its antibody engineering aims to improve efficacy and dosing convenience, potentially capturing significant share if approved.
- Low Beta Provides Defensive Characteristics: With a beta of 0.343, APGE is significantly less volatile than the broader market, unusual for a biotech. This low beta, likely due to the acquisition, offers investors downside protection in turbulent markets.
Bearish
- Zero Revenue and Deep Losses: Apogee reported $0 revenue in Q1 2026 and a net loss of -$74.1 million, up from -$55.3 million a year earlier. The company is entirely dependent on external financing, with negative free cash flow of -$235.4 million TTM.
- Limited Upside to Analyst Targets: The average analyst target price of $130.53 is 2.9% below the current price, and the high target of $137.00 offers only 1.9% upside. This suggests the market has already priced in the acquisition terms, leaving little room for appreciation.
- Analyst Downgrades Post-Acquisition: Following the acquisition announcement, multiple firms (TD Cowen, Stifel, Mizuho, Guggenheim) downgraded APGE from Buy to Hold/Neutral. This reflects reduced expectations for standalone upside and a neutral stance on the deal's accretion.
- Earnings Accretion Delayed Until 2032: AbbVie has stated that meaningful earnings accretion from the acquisition is not expected until 2032. This long timeline introduces execution risk and may limit near-term stock appreciation.
APGE Technical Analysis
Apogee's stock is in a powerful uptrend, with a 1-year price change of +270.29% and a 6-month change of +116.08%. The current price of $134.49 sits at 99.93% of its 52-week range (low $34.34, high $134.58), indicating the stock is trading near its highs, reflecting strong momentum and investor enthusiasm, though it also suggests limited upside in the near term without a breakout. The stock's beta of 0.343 indicates it is significantly less volatile than the broader market, which is unusual for a biotech and may reflect the acquisition-driven price stability.
Beta
0.34
0.34x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$34-$135
Price range past year
Annual Return
+274.6%
Cumulative gain past year
| Period | APGE Return | S&P 500 |
|---|---|---|
| 1m | +1.2% | +2.4% |
| 3m | +62.4% | +4.6% |
| 6m | +116.6% | +11.7% |
| 1y | +274.6% | +21.4% |
| ytd | +77.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APGE Fundamental Analysis
Apogee is a clinical-stage company with zero revenue, as evidenced by the most recent quarter (Q1 2026) reporting revenue of $0. The company's net loss widened to -$74.1 million in Q1 2026 from -$55.3 million in Q1 2025, reflecting increased R&D spending (R&D expenses of $60.8 million in Q1 2026 vs. $46.4 million in Q1 2025). The company remains unprofitable, with a net margin of 0% and an EPS of -$1.06 for Q1 2026. Gross margin is not meaningful as there is no product revenue, and the company's operating margin is negative, consistent with its development stage. The balance sheet is strong with a current ratio of 26.57 and a debt-to-equity ratio of 0.0098, indicating minimal leverage. However, free cash flow is deeply negative at -$235.4 million TTM, and the company is reliant on external financing, as seen in the $411 million raised from stock issuance in Q1 2026. ROE is -28.3%, reflecting significant losses relative to equity.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-235373000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APGE Overvalued?
Given that Apogee has negative net income and no revenue, traditional PE and PS ratios are not meaningful; therefore, we use EV/Sales, but since revenue is zero, we rely on EV/EBITDA, which is -17.54x, indicating the market is valuing the company based on its pipeline potential rather than current financials. The forward PE is -25.92x, and the trailing PE is -17.89x, both negative, reflecting expected continued losses. The PB ratio of 5.07x is high, suggesting investors are paying a premium for the company's assets, likely due to the acquisition premium. Compared to the biotech industry, where average PS ratios are typically around 5-10x for clinical-stage companies, Apogee's PS ratio of 0 is not comparable due to zero revenue. Historically, the stock's PB ratio has ranged from 2.64x to 9.52x over the past three years, and the current 5.07x is near the middle of that range, suggesting the market is pricing in moderate optimism. The PEG ratio is negative, which is not meaningful for a loss-making company.
PE
-17.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-17.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Apogee has zero revenue and is burning cash at an increasing rate, with Q1 2026 net loss of -$74.1 million versus -$55.3 million in Q1 2025. The company's free cash flow is deeply negative at -$235.4 million TTM, and it relies on external financing, having raised $411 million from stock issuance in Q1 2026. While the balance sheet is strong with a current ratio of 26.57 and minimal debt, the ongoing losses and lack of revenue mean the company is entirely dependent on the success of its clinical pipeline and the acquisition by AbbVie. If the acquisition fails or is delayed, Apogee would need to raise additional capital, potentially diluting shareholders significantly.